σ1 and σ2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503

Synapse

Volumn 59, Issue 6, 2006, Pages 350-358

  Lever, John R ^a,b   Gustafson, Jennifer L ^a,b   Xu, Rong ^c   Allmon, Rachel L ^a,b   Lever, Susan Z ^c  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

receptor; Positron emission tomography (PET); SA4503

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1 [2 (4 FLUOROETHOXY 3 METHOXYPHENYL)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1,3 BIS(2 METHYLPHENYL)GUANIDINE; AGY 94806; HALOPERIDOL; IFENPRODIL; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL) 2 PROPENYLAMINE; OPIATE ANTAGONIST; PENTAZOCINE; RADIOLIGAND; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; UNCLASSIFIED DRUG; 1,3 DITOLYLGUANIDINE; 1,3-DITOLYLGUANIDINE; DOPAMINE RECEPTOR BLOCKING AGENT; FE SA4503; FE-SA4503; FLUORINE; GUANIDINE DERIVATIVE; LIGAND; NARCOTIC ANTAGONIST; PIPERAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SIGMA OPIATE RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GUINEA PIG; IC 50; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; AUTORADIOGRAPHY; BINDING COMPETITION; BRAIN; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; FEMALE; MALE; METABOLISM; METHODOLOGY; PROTEIN BINDING; RADIOASSAY;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLUORINE RADIOISOTOPES; GUANIDINES; GUINEA PIGS; HALOPERIDOL; INHIBITORY CONCENTRATION 50; LIGANDS; MALE; NARCOTIC ANTAGONISTS; PENTAZOCINE; PIPERAZINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645410294     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20253     Document Type: Article

References (54)

1. Aydar E, Palmer CP, Djamgoz MB. 2004. Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 64:5029-5035.
2. 3H]DTG binding sites in guinea pig cerebellum: evidence for the presence of non-specific binding. Eur J Pharmacol 252:139-146.
3. Berardi F, Ferorelli S, Colabufo NA, Leopoldo M, Perrone R, Tortorella V. 2001. A multireceptorial binding reinvestigation on an extended class of σ ligands: N-[ω-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards σ1 and EBP sites. Bioorg Med Chem 9:1325-1335.
4. Bergeron R, de Montigny C, Debonnel G. 1999. Pregnancy reduces brain sigma receptor function. Br J Pharmacol 127:1769-1776.
5. Bermack JE, Debonnel G. 2005. Distinct modulatory roles of sigma receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 55:37-44.
6. 2 receptor subtypes. Neuroscience 76:467-477.
7. Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P. 2004. Sigma receptor ligands: applications in inflammation and oncology. Curr Opin Investig Drugs 5:1158-1163.
8. 3H] (+)-pentazocine, a highly selective sigma ligand. Prog Clin Biol Res 328:117-120.
9. Casellas P, Galiegue S, Bourrie B, Ferrini J-B, Jbilo O, Vidal H. 2004. SR31747A: a peripheral σ ligand with potent antitumor activities. Anticancer Drugs 15:113-118.
10. Chaki S, Tanaka M, Muramatsu M, Otomo S. 1994. NE-100, a novel potent sigma ligand, preferentially binds to sigma 1 binding sites in guinea pig brain. Eur J Pharmacol 251:R1-R2.
11. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
12. 1 receptors of guinea pig brain. Synapse 55:192-195.
13. 1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol 370:106-113.
14. Collier TL, Lecomte R, McCarthy TJ, Meikle S, Ruth TJ, Scopinaro F, Signore A, VanBrocklin H, van De Wiele C, Waterhouse RN. 2002. Assessment of cancer-associated biomarkers by positron emission tomography: advances and challenges. Dis Markers 18:211-247.
15. de Costa BR, He XS, Dominguez C, Cutts J, Williams W, Bowen WD. 1994. A new approach to the design of σ-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) ethylamine-related polyamines at σ-1 and σ-2 receptor subtypes. J Med Chem 37:314-321.
16. 3H](+)-pentazocine to sigma recognition sites in guinea pig brain. Eur J Pharmacol 227:371-378.
17. 3H]1,3-di(2-tolyl) guanidine binds to a sigma 2 receptor on Jurkat cell membranes, but sigma compounds fail to influence immunomodulatory events in human peripheral blood lymphocytes. Immunopharmacology 35:27-39.
18. Elsinga PH, Kawamura K, Kobayashi T, Tsukada H, Senda M, Vaalburg W, Ishiwata K. 2002. Synthesis and evaluation of [18F]fluoroethyl SA4503 as a PET ligand for the sigma receptor. Synapse 43:259-267.
19. Elsinga PH, Tsukada H, Harada N, Kakiuchi T, Kawamura K, Vaalburg W, Kimura Y, Kobayashi T, Ishiwata K. 2004. Evaluation of [18F]fluorinated sigma receptor ligands in the conscious monkey brain. Synapse 52:29-37.
20. Fujimura K, Matsumoto J, Niwa M, Kobayashi T, Kawashima Y, In Y, Ishida T. 1997. Synthesis, structure and quantitative structure-activity relationships of sigma receptor ligands, 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines. Bioorg Med Chem 5:1675-1683.
21. Gebreselassie D, Bowen WD. 2004. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol 493:19-28.
22. Guitart X, Codony X, Monroy X. 2004. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl) 174:301-319.
23. 3H]ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 236:159-163.
24. Hayashi T, Su T-P. 2004. σ-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18:269-284.
25. Ishii K, Ishiwata K, Kimura Y, Kawamura K, Oda K, Senda M. 2001. Mapping of sigma-1 receptors in the living human brain. Neuroimage 13:S984.
26. 11C]SA4503. Synapse 40:235-237.
27. 3H]SA4503 to sigma1 receptors in the rat brain. Ann Nucl Med 17:73-77.
28. Kawamura K, Kimura Y, Tsukada H, Kobayashi T, Nishiyama S, Kakiuchi T, Ohba H, Harada N, Matsuno K, Ishii K, Ishiwata K. 2003a. An increase of sigma receptors in the aged monkey brain. Neurobiol Aging 24:745-752.
29. 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl]-4-(3-phenylpropyl) piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol 30:273-284.
30. Leitner ML, Hohmann AG, Patrick SL, Walker JM. 1994. Regional variation in the ratio of σ1 to σ2 binding in rat brain. Eur J Pharmacol 259:65-69.
31. Levi MS, Brimble MA. 2004. A review of neuroprotective agents. Curr Med Chem 11:2383-2397.
32. Mach RH, Smith CR, Childers SR. 1995. Ibogaine possesses a selective affinity for σ2 receptors. Life Sci 57:PL57-PL62.
33. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. 1997. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 57:156-161.
34. Matsuno K, Mita S. 1998. SA4503: a novel sigma1 receptor agonist. CNS Drug Rev 4:1-24.
35. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. 1996. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 306:271-279.
36. Matsuno K, Senda T, Kobayashi T, Okamoto K, Nakata K, Mita S. 1997. SA4503, a novel cognitive enhancer, with σ1 receptor agonistic properties. Behav Brain Res 83:221-224.
37. Maurice T. 2004. Neurosteroids and σ1 receptors, biochemical and behavioral relevance. Pharmacopsychiatry 37:S171-S182.
38. Maurice T, Phan V-L, Urani A, Kamei H, Noda Y, Nabeshima T. 1999. Neuroactive neurosteroids as endogenous effectors for the sigma1 (σ1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 81:125-155.
39. Maurice T, Martin-Pardon R, Romieu P, Matsumoto RR. 2002. Sigma1 (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 26:499-527.
40. 1 receptor-mediated behaviours are related to neurosteroid levels. Eur J Neurosci 15:1523-1534.
41. 3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands. Mol Pharmacol 39:222-232.
42. Senda T, Matsuno K, Mita S. 1995. Differences in the high affinity sites of sigma receptors between guinea pig and rat brain. Neurosci Res Commun 17:97-105.
43. Skuza G. 2003. Potential antidepressant activity of sigma ligands. Polish J Pharmacol 55:923-934.
44. Skuza G, Wedzony K. 2004. Behavioral pharmacology of sigma-ligands. Pharmacopsychiatry 37 (Suppl. 3):S183-S188.
45. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. 1985. Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
46. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MVL, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S. 2004. Small molecule antagonists of the σ-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 64:4875-4886.
47. Su T-P, London ED, Jaffe JH. 1988. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 240:219-221.
48. 11C-SA4503: a feasibility study. J Nucl Med 45:1939-1945.
49. Volz HP, Stoll KD. 2004. Clinical trials with sigma ligands. Pharmacopsychiatry 37:214-220.
50. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. 1990. Sigma receptors: biology and function. Pharmacol Rev 42:355-402.
51. 3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparative study. Brain Res 581:33-38.
52. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH. 2000. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 82:1223-1232.
53. 1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298:1269-1279.
54. Urfer R, Rickhag M, Oksenberg D, Gido G, Shamloo M, Lohr S, Murray J, Krogh M, Johansson B, Nikolich K, Wieloch T. 2005. A new approach to enhancement of functional recovery after stroke by genomics analysis of the enriched environment model. Intl Stroke Conf, New Orleans, LA. Abstract 50.